Meet the Proteona team at the 9th Mildred Scheel Cancer Conference in Bonn, Germany
Innovative genomic and proteomic analysis platform for Immuno-Oncology and Single Cell BioMedical Applications
Dr Andreas Schmidt, the CEO of Proteona, will attend the 9th Mildred Scheel Cancer Conference from the 15th to the 16th May, 2019. The biennial conference, this year taking place in Bonn, Germany, focuses on important topics such as cancer immunotherapy and personalized medicine.
Dr Schmidt will be available during the conference to discuss how single cell analysis using Proteona’s ESCAPE platform can help advancing novel immunotherapies and understanding patient response, such as CAR T-cell immunotherapy.
For media queries, please contact:
Dr Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).